Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.
周二,Silexion Therapeutics Corp.(纳斯达克股票代码:SLXN)股价在盘前交易中上涨了21.72%以上,此前该公司公布了其第一代产品LODER的二期试验的新发现。
Overall, the updated analysis reveals a 56% objective response rate (ORR) in patients treated with LODER, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable.
总体而言,最新的分析显示,接受LODER治疗的患者的客观缓解率(ORR)为56%,而以前不可切除的肿瘤可切除的患者的客观缓解率(ORR)增加到67%。
Silexion had previously reported that patients treated with LODER combined with standard-of-care (SoC) chemotherapy experienced a 9.3-month improvement in overall survival (OS) compared to chemotherapy alone.
Silexion此前曾报告说,与单独的化疗相比,接受LODER联合标准护理(SoC)化疗的患者的总存活率(OS)提高了9.3个月。
The new data now underscores LODERs additional potential to increase the resectability of tumors, opening up more surgical options for patients with otherwise inoperable pancreatic cancer.
现在,新数据突显了LODers增加肿瘤可切除性的额外潜力,为原本无法手术的胰腺癌患者开辟了更多的手术选择。
Silexion is also progressing with the development of its next-generation product, SIL-204, which builds upon the efficacy of the LODER.
Silexion在开发其下一代产品 SIL-204 方面也在取得进展,该产品建立在LODER功效的基础上。
SIL-204 is designed to target a broader range of KRAS mutations.
SIL-204 旨在靶向更广泛的 KRAS 突变。
In August, Silexion Therapeutics and Moringa Acquisition Corp, a publicly-traded special purpose acquisition company, combined with Biomotion Sciences.
8月,Silexion Therapeutics和上市的特殊目的收购公司辣木收购公司与Biomotion Sciences合并。
The combined company's name changed from Biomotion Sciences to Silexion Therapeutics.
合并后的公司名称从Biomotion Sciences改为Silexion Therapeutics。
Price Action: SLXN stock is up 18.3% at $0.91 during the premarket session at last check Tuesday, according to Benzinga Pro.
价格走势:根据Benzinga Pro的数据,在周二的最后一次盘前交易中,SLXN股价上涨18.3%,至0.91美元。
- T-Mobile To Raise $2.5B Via Debt For Buybacks and Growth.
- T-Mobile将通过债务筹集25亿美元用于回购和增长。